Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.

Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C.

Ann Surg Oncol. 2012 Feb;19(2):627-35. doi: 10.1245/s10434-011-2030-7. Epub 2011 Aug 31.

PMID:
21879272
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases.

Rossi CR, Pasquali S, Mocellin S, Vecchiato A, Campana LG, Pilati P, Zanon A, Nitti D.

Ann Surg Oncol. 2010 Nov;17(11):3000-7. doi: 10.1245/s10434-010-1104-2. Epub 2010 Apr 29.

PMID:
20429035
[PubMed - indexed for MEDLINE]
3.

Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.

Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, Kuppen PJ, van de Velde CJ, Tollenaar RA.

Melanoma Res. 2004 Feb;14(1):67-72.

PMID:
15091197
[PubMed - indexed for MEDLINE]
4.

Results of regional isolated perfusion for locally inoperable melanoma of the limbs.

Kapteijn BA, Klaase JM, van Geel AN, Eggermont AM, Kroon BB.

Melanoma Res. 1994 Apr;4(2):135-8.

PMID:
8069099
[PubMed - indexed for MEDLINE]
5.

Hyperthermic isolation-perfusion with melphalan, a preliminary appraisal of local and general effects in malignant melanoma.

Lejeune FJ, Mathieu M, Kenis Y.

Tumori. 1977 May-Jun;63(3):289-98.

PMID:
898296
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk